New vaccine combo aims to supercharge immune attack on breast cancer
NCT ID NCT03632941
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a HER2-targeting vaccine (VRP-HER2) to the immunotherapy drug pembrolizumab could boost the immune system's attack on advanced HER2-positive breast cancer. Eight participants were randomly assigned to receive the vaccine alone, pembrolizumab alone, or both together. The main goal was to see if the combination increased T-cell activity against the cancer, while also monitoring safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HER2-OVEREXPRESSING BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple